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ABSTRACT
A substantial fraction of patients with stage I–III colorectal adenocarcinoma (CRC) experience disease relapse 
after surgery with curative intent. However, biomarkers for predicting the likelihood of CRC relapse have not 
been fully explored. Therefore, we assessed the association between tumor infiltration by a broad array of 
innate and adaptive immune cell types and CRC relapse risk. We implemented a discovery-validation design 
including a discovery dataset from Moffitt Cancer Center (MCC; Tampa, FL) and three independent validation 
datasets: (1) GSE41258 (2) the Molecular Epidemiology of Colorectal Cancer (MECC) study, and (3) GSE39582. 
Infiltration by 22 immune cell types was inferred from tumor gene expression data, and the association between 
immune infiltration by each cell type and relapse-free survival was assessed using Cox proportional hazards 
regression. Within each of the four independent cohorts, CD4+ memory activated T cell (HR: 0.93, 95% CI: 
0.90–0.96; FDR = 0.0001) infiltration was associated with longer time to disease relapse, independent of stage, 
microsatellite instability, and adjuvant therapy. Based on our meta-analysis across the four datasets, 10 innate 
and adaptive immune cell types associated with disease relapse of which 2 were internally validated using 
multiplex immunofluorescence. Moreover, immune cell type infiltration was a better predictors of disease 
relapse than Consensus Molecular Subtype (CMS) and other expression-based biomarkers (Immune-AICMCC 
:238.1–238.9; CMS-AICMCC: 241.0). These data suggest that transcriptome-derived immune profiles are prog-
nostic indicators of CRC relapse and quantification of both innate and adaptive immune cell types may serve as 
candidate biomarkers for predicting prognosis and guiding frequency and modality of disease surveillance.
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Of the patients with localized stage I–III colorectal cancer (CRC) 
who underwent surgical resection, 18% will typically experience 
distal relapse within the first three years following initial treat-
ment with curative-intent.1 Although post-operative surveillance 
is an important aspect of clinical care, variability exists in the 
follow-up strategies employed by physicians (e.g., modality and 
frequency) for localized cancers. Therefore, there is no consen-
sus on the optimal intervals for disease surveillance with the goal 
of detecting disease relapse,2–4 and improved approaches for 
assessing risk of disease relapse are needed.
Mounting evidence has implicated the tumor immune micro-
environment (TME) in governing CRC relapse in early and 
advanced stages of disease.5,6 Tumor infiltration by tumor- 
infiltrating lymphocytes (TILs)7 and specific T cell subsets, such 
as CD8+ cytotoxic T cells and CD45RO-marked CD4+ memory 
T cells, have been associated with an improved prognosis in CRC 
across multiple studies.8,9 Application of Immunoscore, an immu-
nohistochemistry (IHC) based scoring system summarizing the 
CONTACT Stephanie L.Schmit Stephanie.Schmit@moffitt.org Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
H. Robert Frost, Christopher I. Amos, and Stephanie L. Schmit jointly supervised this work.
Supplemental data for this article can be accessed on the publisher’s website.
ONCOIMMUNOLOGY                                        
2021, VOL. 10, NO. 1, e1862529 (12 pages) 
https://doi.org/10.1080/2162402X.2020.1862529
© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
density of CD3+ and CD8+ T cells within a CRC tumor and its 
invasive margins, suggests that the TME of primary tumors can 
estimate time to disease relapse.10 Although Immunoscore and 
measures of TILs have both been inversely associated with disease 
relapse, opportunities exist to further refine our understanding of 
the TME and its role in cancer progression. First, most studies 
have examined the role of immune infiltration in predicting CRC 
relapse using traditional pathology and IHC techniques. These 
approaches are subject to pathologist variability, whereas tran-
scriptomic profiles objectively measure genome-wide expression. 
Second, while previous studies have primarily focused on lym-
phocytes, a broader examination of diverse innate and adaptive 
immune cell subtypes, including myeloid cell lineages, is 
warranted.11,12 Specifically, innate immune cells, such as mono-
cytes, can be reprogrammed by cancer cells to promote tumor cell 
invasion and growth.13 Third, the predictive role of the TME has 
not been fully established in the setting of adjuvant therapy. 
Standard of care adjuvant chemotherapy and/or radiation treat-
ment following surgical resection with curative intent can alter the 
TME and impact disease relapse. Thus, it is important to assess the 
prognostic value of the TME after adjusting for adjuvant therapy. 
Last, the predictive value of tumor immune infiltration should be 
compared to other molecular prognostic factors derived from 
transcriptomic profiles such as the consensus molecular subtype 
(CMS) classification of CRC14 to fully assess the value of the TME 
at diagnosis as a prognostic biomarker.
Here, we investigated the association between infiltration 
by specific immune cell types and CRC relapse, adjusting for 
known prognostic indicators including receipt of adjuvant 
therapy. We also compared the predictive accuracy of 
immune infiltration scores of individual cell types and their 
combinations to other well-known transcriptome-derived 




Employing a computational deconvolution approach and 
a discovery-validation design, we quantified tumor infiltration 
of 22 immune cell types from CRC transcriptomic profiles 
across four independent studies. The discovery dataset 
included cases from the Total Cancer Care Protocol15 at 
Moffitt Cancer Center, referred to as the MCC dataset. Three 
datasets, GSE41258, the Molecular Epidemiology of Colorectal 
Cancer study (MECC), and GSE39582, provided independent 
validation of the utility of these biomarkers (Table 1). These 
studies were selected for validation purposes as they contain 
comprehensive clinical information on patients that allowed us 
to account for the effects of age, sex, stage at diagnosis, MSI 
status, and adjuvant therapy status when examining the asso-
ciation of 22 immune cell types with disease relapse. Baseline 
characteristics for all datasets are listed in Table 1. The primary 
outcome of interest is disease relapse. Disease relapse is defined 
as either a local (e.g. anastomosis site) or distal (e.g. lung, liver) 
disease relapse or CRC-specific death in patients with stage I– 
III tumors. Time to disease relapse was defined as the time 
from surgical resection with curative-intent to time of local or 
distal disease relapse or time to CRC-related death. For patients 
without a documented relapse or CRC-related death, survival 
times were censored at last follow-up or non-CRC specific 
death. Disease relapse information was available for the MCC 
and GSE41258 datasets. Disease-specific survival was available 
for the MECC dataset. Relapse-free survival was the primary 
outcome in the GSE39582 dataset.
Discovery: Total Cancer Care MCC dataset
The discovery population (MCC) consisted of 134 stage I–III 
and 40 stage IV colorectal adenocarcinoma patients diagnosed 
at Moffitt Cancer Center between May 1994 and 
September 2010.16 Primary analyses examining disease relapse 
were performed on stage I–III tumors, while CRC-specific 
death was the primary endpoint for analyses performed on 
stage IV-only tumor samples. Inclusion and exclusion criteria 
for the study sample are summarized in Supplementary Fig. S1.
Microarray gene expression data for all samples were curated 
by the MCC Biostatistics and Bioinformatics Shared Resource. 
All samples passed multiple standard quality controls, and all 
transcriptomic data analyzed were previously deposited to the 
Gene Expression Omnibus (GEO) site curated by the National 
Center for Bioinformatics (GSE131418), where associated clin-
ical data can be found (see supplemental methods).
Validation datasets: GSE41258, MECC, GSE39582
The first validation dataset, GSE41258, is a publicly available 
dataset containing information on disease relapse, CRC-specific 
death, and corresponding clinical information including age, sex, 
stage at diagnosis, and microsatellite instability (MSI) status, for 
169 patients with stage I–IV tumors.17 The second validation set 
consists of gene expression microarray data from the Molecular 
Epidemiology of Colorectal Cancer (MECC) study, a population- 
based case-control study in northern Israel (GSE26682). This 
study was used to validate associations with CRC-specific 
survival.18 The MECC gene expression dataset consists of 270 
patients with stage I–IV tumors and corresponding clinical infor-
mation, including MSI status. CRC-specific five-year survival in 
MECC was used as the outcome of interest (see Supplemental 
Methods). The third validation dataset, GSE39582, is also 
a publicly available dataset containing information on relapse- 
free survival and corresponding clinical information includes 
age, sex, stage at diagnosis, MSI status, and adjuvant therapy status 
for 507 patients with stage I–IV tumors.19 Relapse-free survival in 
GSE39582 was used as the primary outcome of interest. Analyses 
of all four datasets were restricted to participants with stage I–III 
tumors, except where specifically noted for the exploration of 
disease-specific survival in patients with stage IV disease.
Quantification of tumor immune infiltration, consensus 
molecular subtype (CMS) classification, and pathway 
enrichment analysis
We applied the BASE deconvolution algorithm20 implementing 
the LM22 matrix from CIBERSORT21 to estimate the infiltration 
of 22 immune cell types from bulk tumor gene expression data 
(see Supplemental Methods). The 22 immune cell types examined 
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are listed in Supplementary Table S1. We also implemented the 
MCP Counter method to compare the predictive performance of 
our BASE immune infiltration method with existing deconvolu-
tion approaches.22 Furthermore, we measured relative T cell frac-
tion using the DNA-based immunoSEQ assay (Adaptive 
Biotechnologies, Seattle, WA) on a subset of patients in the 
MECC validation dataset (n = 231; see Supplemental Methods).
CMS is a transcriptome-based classification of CRC with inde-
pendent prognostic value.14 Tumors were classified into CMS 
groups 1–4 or CMS_NA using the R package CMSclassifier, 
with a posterior probability of 0.5..14 The CMS4 group was set 
as the reference CMS group for all comparative analyses.
Transcriptomic activity of pathways from the Hallmark and 
C2. Reactome Collections in the Molecular Signature Database 
(MSigDB V6.0)23 was quantified for each tumor sample. 
Estimates of pathway activity were then used as inputs in down-
stream regression models examining the association between 
specific pathways and disease relapse adjusting for appropriate 
clinical variables. Using Spearman rank correlation, pathways that 
were associated with disease relapse in a multivariable Cox model 
(FDR <0.1) were then correlated with infiltration scores of indi-
vidual immune cell types, which also independently associated 
with disease relapse. Pathways defined by genes that overlapped 
with the gene set defining the immune cell signatures were 
identified and the degree of shared overlap in genes was quantified 
for each pathway. We specifically focused on pathways that did 
not share genes with the immune-defining signature gene set. This 
allowed us to ensure that immune cell-pathway correlations were 
detecting true correlations between immune cell type infiltration 
and tumor pathway activity and that correlations were not driven 
by shared gene expression. Pathways enriched in the discovery 
MCC dataset were validated in the GSE41258 dataset (see 
Supplementary Methods).
Validation of transcriptome-derived tumor immune 
infiltration scores
Multiplex immunofluorescence (mIF) was performed on 
tumor cores embedded in tissue microarray (TMA)
blocks for a subset of patients in the MCC (N = 68) and MECC 
(N = 99) datasets to quantify and validate CD8+ T cell and 
memory T cell infiltration score estimates from bulk transcrip-
tomic data. We calculated Spearman’s rank correlation coefficient 
between densities of CD3+/CD8+ cells and CD3+/CD45RO cells 
and CD8 T cell and memory T cell (resting and activated) tran-
scriptome-derived immune infiltration scores, respectively. 
Additional details can be found in the Supplementary Methods.
Table 1. Baseline clinical characteristics for MCC, GSE41258, MECC, and GSE39582 participants.
MCC (n = 174) GSE41258 (n = 169) MECC (n = 270) GSE39582 (n = 507)
Age at Diagnosis (yr), mean (SD) 64.94 (12.4) 63.0 (14.1) 71.62 (11.3) 67.22 (13.2)
Race/Ethnicity (%)
White 162 (93.1%)
Black/African American 8 (4.6%)





Male 90 (51.7%) 88 (52.1%) 143 (53.0%) 285 (56.2%)
Female 84 (48.3%) 81 (47.9%) 127 (47.0%) 222 (43.8%)
Adjuvant Therapy (%)
Yes 88 (50.6%) 224(44.2%)
No 84 (48.3%) 283(55.8%)
Unknown 2 (1.1%) 169 (100%) 270 (100%)
Anatomical Origin (%)
Proximal Colon 86 (49.4%) 71 (42.0%) 113 (41.9%) 207 (40.8%)
Distal Colon 55 (31.6%) 84 (49.7%) 106 (39.3%) 300 (59.2%)
Rectum 33 (19.0%) 14 (8.3%) 42 (15.5%)
Unknown 9 (3.3%)
Microsatellite Instability Status (%)
MSI 4 (2.3%) 35 (20.7%) 37 (13.7%) 72 (14.2%)
MSS 23 (13.2%) 124 (73.4%) 233 (86.3%) 435 (85.8%)
Unknown 147 (84.5%) 10 (5.9%)
Primary Pathological Tumor Stage (%)
Stage 1 37 (21.3%) 27 (16.0%) 21 (7.8%) 36 (7.1%)
Stage 2 51 (29.3%) 46 (27.2%) 131 (48.5%) 225 (44.4%)
Stage 3 46 (26.4%) 46 (27.2%) 105 (38.9%) 203(40.0%)
Stage 4 40 (23.0%) 50 (29.6%) 13 (4.8%) 43 (8.5%)
Consensus Molecular Subtypes (%)
CMS1 19 (10.9%) 29 (17.2%) 31 (11.5%) 62 (12.2%)
CMS2 46 (26.4%) 67 (39.6%) 99 (36.7%) 173 (34.1%)
CMS3 37 (21.2%) 11 (6.5%) 27 (10%) 81(16.0%)
CMS4 36 (20.6%) 22 (13.0%) 45 (16.7%) 110 (21.7%)
CMS_NA 36 (20.6%) 40 (23.7%) 68 (25.2%) 81 (16.0%)
Relapse Events (%) 27 (20.1%) 22 (17.9%) 154 (30.4%)
CRC-specific Death Events (%) 45 (25.9%) 62 (36.7%) 96 (35.6%)
Median Follow-up Time (months) 108.13 66 80.91 45
Median Follow-up (months) for Event* 12.57 19 30.11 13.5
Notes: All analyses examining relapse as an endpoint excluded stage 4 tumors, while all analyses examining disease-specific survival as an endpoint included stage 4 tumors. 
Median follow-up until an event refers to a relapse event for the MCC, GSE41258, and GSE39582 datasets and a CRC-specific cause of death for the MECC dataset.
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Statistical analysis
Statistical significance testing of differences in infiltration score 
means was performed using the Wilcoxon rank sum test. Cox 
proportional hazards models were used to perform univariate and 
multivariate analyses to determine the association of immune cell 
types and pathways with time to disease relapse and CRC-specific 
survival in patients with stage I–III tumors. CMS group associa-
tion with disease relapse was assessed to compare the performance 
of CMS groups and immune cell types in predicting disease 
relapse. All multivariable Cox-regression models adjusted for 
age, sex, and stage. For the MCC and GSE39582 datasets, we 
also adjusted for adjuvant therapy. Treatment information, 
including adjuvant therapy status was unavailable for the MECC 
and GSE41258 datasets. However, for the MECC, GSE41258, and 
GSE39582 datasets, we adjusted for MSI status. The MCC dataset 
did not have sufficient information for MSI adjustment. The 
association of CMS groups with disease relapse was assessed 
using both a logistic regression framework and Chi-Square test. 
In order to evaluate consistency of results across study cohorts, 
a meta-analysis was performed using results from all four datasets 
(see Supplemental Methods; Supplementary Table S2). For the 
MCC and GSE41258 datasets, which had the most sensitive 
measures of disease relapse, we compared the predictive perfor-
mance of gene-expression derived estimates of infiltrating 
immune cells with CMS groups and single-gene (e.g., CD8A 
and CD3D) predictors using the Akaike Information Criterion 
(AIC). All regression models of interest were also compared to 
a null model, which examined the association between disease 
relapse and clinical variables only, using the likelihood ratio test 
(LRT). We also compared the predictive performance of gene- 
expression derived estimates of infiltrating immune cells with 
immunoSEQ T cell fraction for disease relapse on the subset of 
patients in the MECC validation dataset with both data sources. 
All p-values and confidence intervals are reported without adjust-
ment for multiple hypothesis testing unless indicated otherwise. 
All statistical analyses were performed in R (Versions 3.4 & 3.5).
Results
Tumor infiltration by innate and adaptive immune cells is 
associated with disease relapse
We estimated tumor immune infiltration from gene expression 
profiles of tumors and examined the association between infiltra-
tion by each immune cell type and time to disease relapse (Figure 
1). In the MCC discovery dataset, high infiltration by several T cell 
subsets, including CD8+ T cells and CD4+ memory T cells (rest-
ing and activated), was associated with improved prognosis. 
Monocytic infiltration was associated with poor prognosis and 
disease relapse (Supplementary Fig. S2). B cell, T cell, macrophage, 
and dendritic cell subsets were all associated with stage at diag-
nosis, while only resting dendritic cells were associated with 
administration of adjuvant therapy (Supplementary Fig. S3–4). 
Tumor immune infiltration for all 22 cell types did not differ 
based on tumor anatomical origin (Supplementary Fig. S5). 
Therefore, we did not adjust for tumor anatomical origin when 
determining the association of the TME with disease relapse. In 
the discovery dataset (MCC), CD8+ T cell (HR: 0.92; 95% CI: 
0.84–0.99; P =.04), CD4+ memory resting T cell (HR: 0.89; 95% 
CI: 0.80–0.99; P =.02), CD4+ memory activated T cell (HR: 0.91; 
95% CI: 0.83–0.99; P =.03), and CD4+ Naïve T cell (HR: 0.91; 95% 
CI: 0.83–0.99; P =.04) infiltration scores were associated with 
a lower risk of CRC relapse. Monocyte (HR: 1.07; 95% CI: 1.01–-
1.15; P =.03) and neutrophil (HR: 1.07; 95% CI: 1.00–1.14; P =.04) 
infiltration was associated with an increased risk of disease relapse 
after adjusting for known prognostic clinical variables. However, 
given the strong association between CMS1 and MSI-high status, 
we also considered CMS1 as an imperfect proxy for MSI in 
sensitivity analyses and found that CD8+ T cells and CD4+ 
memory (resting and activated) T cells remained strong predictors 
of having a lower risk of disease relapse and fewer disease-relapse 
events. Monocytes and neutrophils remained strong predictors of 
worse prognosis and a shorter time to disease relapse 
(Supplementary Table S3). These results were replicated across 
three validation datasets, where MSI information was available 
and appropriately adjusted for in all regression analyses.
In the GSE41258 dataset, CD8+ T cell and CD4+ memory 
(resting and activated) T cells were associated with lower risk of 
disease relapse, while monocyte infiltration was associated with 
increased risk of disease relapse (Figure 1). Notably, in the 
GSE41258 dataset, NK resting cells (HR: 0.84; 95% CI: 0.71–0.99; 
P =.04) were also associated with lower risk of disease relapse.
The association between CD8+ T cells, CD4+ memory activated 
T cells, and disease relapse in patients with stage I–III disease was 
replicated in the MECC dataset (Figure 1). The associations for CD4 
+ memory resting T cells and monocytes with disease relapse were 
also trending in the same direction as observed for the MCC dataset 
(Figure 1). In MECC, NK (resting and activated) cells, activated 
dendritic cells, and gamma-delta T cells were also strongly associated 
with improved CRC-specific five-year survival (Figure 1).
In the GSE39582 dataset, where we were able to account for the 
effects of both adjuvant therapy and MSI status information on dis 
ease relapse, the association between CD4+ memory activated T cell 
(HR: 0.95; 95% CI: 0.91–0.99; P =.02) and disease relapse was replicated. 
Activated NK cell (HR: 0.94; 95% CI: 0.89–0.99; P = 
.03), activated dendritic cell (HR: 0.98; 95% CI: 0.96–0.99; P =.04), and 
M1 macrophage (HR: 0.98; 95% CI: 0.99–1.06; P =.05) infiltration was 
also associated with a lower risk of disease-relapse in this dataset.
Using a meta-analysis framework, we demonstrated that over-
all the strongest predictors of disease-relapse risk observed across 
all four datasets were CD4+ memory activated T cells (Figure 1; 
HR: 0.93, 95% CI: 0.90–0.96; FDR = 0.0001), NK activated cells 
(Figure 1; HR: 0.93; 95% CI: 0.90–0.97; FDR = 0.002), monocytes 
(Figure 1; HR: 1.03; 95% CI: 1.01–1.06; FDR = 0.01), NK resting 
cells (Figure 1; HR: 0.94; 95% CI: 0.89–0.98; FDR = 0.02), activated 
dendritic cells (Figure 1; HR: 0.98; 95% CI: 0.97–0.99; FDR = 0.02), 
resting mast cells (Figure 1; HR: 1.05; 95% CI: 1.01–1.08; 
FDR = 0.02), M2 macrophages (Figure 1; HR: 1.03; 95% CI: 
1.007–1.05; FDR = 0.03), M1 macrophages (Figure 1; HR: 0.98; 
95% CI: 0.97–0.99; FDR = 0.05) and neutrophils (Figure 1; HR: 
1.03; 95%CI:1.00–1.05; FDR = 0.07). While immune infiltration by 
CD8+ T cells was strongly associated with a lower disease relapse 
risk in some individual datasets, CD8+ T cell infiltration was less 
strongly associated with disease relapse in the meta-analysis 
(Figure 1; HR: 0.93; 95% CI: 0.86–0.99; FDR = 0.10). This is likely 
due to the heterogeneity observed between datasets (heterogeneity 
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p-value = 0.008; Supplementary Table S2). CD4+ memory acti-
vated T cell and CD8+ T cell immune infiltration scores were 
internally validated using multiplex immunofluorescence TMA 
cores from N = 68 MCC patients and N = 99 MECC patients 
using (see Supplementary Results; Supplementary Fig. S6).
Specifically, CD4+ memory activated T cells, NK cells 
(resting and activated), M1 macrophages, and activated den-
dritic cells were all associated with a lower risk of disease 
relapse and having fewer disease relapse events. In contrast, 
monocyte, M2 macrophage, neutrophil, and resting mast cell 
infiltration was associated with a higher risk of disease relapse 
and having more disease relapse events (Figure 1; FDR < 0.1). 
Interestingly, although not significantly associated with dis-
ease relapse in any of the individual datasets, joint statistical 
analysis of the discovery and validation datasets was able to 
demonstrate the association of resting mast cell infiltration 
with shorter time to disease relapse (FDR < 0.05; Figure 1; 
Supplementary Table S2).
Immune-immune interactions between regulatory T cells 
and eosinophils are significant predictors of disease 
relapse
Immune–immune interactions have known biologically rele-
vance including modulating the TME. Therefore, we aimed to 
examine immune-immune interactions in the TME in order to 
determine if statistical interactions between immune cells have 
predictive value for estimating disease relapse. Therefore, we 
examined immune interactions using risk modeling. Using 
lasso penalized regression on the MCC dataset, the following 
immune cells and their combinations with non-zero coeffi-
cients at the minimum lambda were selected for risk modeling: 
CD4+ memory resting T cells, monocytes, regulatory T cells, 
eosinophils, and the interaction between regulatory T cells and 
eosinophils (Figure 2(a)). A risk score, dubbed the “immune + 
clinical model”, was developed using these immune cell com-
binations and clinical variables of interest as predictors. 
Patients with high-risk scores were then compared to patients 
Figure 1. Immune infiltration and disease relapse association. The association between disease relapse and relative immune infiltration of 22 immune cell types in CRC 
samples across four datasets – MCC (n = 134), GSE41258 (n = 119), MECC (n = 257), GSE39582 (n = 464) – in stage I–III tumors was examined using multivariable Cox 
regression modeling. For all datasets, the association of each immune cell type with disease relapse was determined while adjusting for age, sex, adjuvant therapy 
treatment, microsatellite instability (MSI) status, and stage at diagnosis. For the GSE41258 and MECC datasets, adjuvant treatment status was not available while MSI 
information was not available for the MCC dataset. For the MECC dataset, the association between relative immune infiltrates and CRC-specific death was determined. 
Overall, 22 regression models were performed for each dataset. The coefficients for each immune cell type are displayed with their respective confidence intervals. 
A joint meta-analysis was performed based on results from across the four studies so that the collective association of immune cell infiltration on disease relapse could 
be examined. Meta-analysis is presented with the FDR-adjusted p-values for each immune cell type.
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with low-risk scores in order to determine if the “immune + 
clinical model” based risk score was predictive of disease 
relapse. The “immune + clinical model” risk score was devel-
oped using the MCC dataset and validated on the GSE41258 
dataset (Figure 2(c)). Similarly, a risk score was developed 
using only clinical variables, dubbed the “clinical model” risk 
score (Figure 2(b)), which was also trained on the MCC dataset 
and validated on the GSE41258 dataset. This allowed us to 
compare the performance of the immune-based risk score 
with the clinical covariate-based risk score in predicting disease 
relapse. High-low dichotomization of the clinical-based risk 
scores and the immune-based risk scores showed that the 
immune-based risk scores best-predicted disease relapse in 
the GSE41258 dataset (Figure 2(c)). These findings highlight 
the relevance of examining combinations of immune cell types 
and their collective impact on disease relapse rather than 
examining one immunological cell type at a time.
Tumor immune infiltration is a better predictor of time to 
CRC relapse than other transcriptome-based biomarkers
Other molecular stratification schemes, such as CMS and 
CD8A and CD3D gene expression, have previously been 
shown to be predictive of clinical outcomes in CRC. 
Therefore, we aimed to determine if tumor immune infiltra-
tion estimates inferred from the transcriptome are better 
predictors of disease relapse than these known transcriptomic 
signatures or clinical variables alone. Specifically, we com-
pared the performance of CD4+ memory (resting and acti-
vated) T cells, CD8+ T cell, CD4+ naïve T cell, monocyte, and 
neutrophil infiltration with these other molecular stratifica-
tion schemes, as these cell types were strongly associated with 
disease relapse in stage I–III tumors in our discovery MCC 
dataset. CD8+ T cell (AICMCC: 239.5; AICGSE41258: 172.4), 
monocyte (AICMCC: 238.9; AICGSE41258: 178.4), CD4+ mem-
ory resting T cell (AICMCC: 238.1; AICGSE41258: 178.2), and 
CD4+ memory activated T cell (AICMCC: 239.1; AICGSE41258: 
175.1) infiltration were better predictors of disease relapse 
than CMS (AICMCC: 241.0; AICGSE41258: 184.6), clinical vari-
ables alone (Table 2), CD8A expression (AICMCC: 243.9; 
AICGSE41258: 182.2), and CD3D expression (AICMCC: 243.0; 
AICGSE41258: 181.4) in both MCC and GSE41258 where dis-
ease relapse in stage I–III tumors were directly assessed 
(Table 2). Last, no single CMS group was consistently asso-
ciated with time to disease relapse using multivariable mod-
eling in either the MCC or GSE41258 datasets. However, the 
proportion of CMS4 tumors was higher in patients with 
a disease relapse event compared to patients without relapse 
(Figure 2(a)) in the MCC dataset (MCC; χ2 test p-value = 0.03). 
CMS group did not predict CRC relapse better than any 
model examining immune infiltration or clinical variables 
alone, thereby further highlighting the prognostic value of 
expression-derived immune infiltration over CMS 
classification.
Figure 2. Immune infiltration and risk model prediction. Using least absolute shrinkage and selection operator (Lasso) regression modeling, immune predictors and their 
combinations that associate with disease relapse were selected for risk modeling. All models were trained on the MCC dataset and applied to the GSE41258 validation 
dataset. The immune model was developed using the Lasso selected immune variable and includes the clinical variables age, sex, and stage (a). The clinical model was 
developed only using the clinical variables age, sex, and stage (b). The outputs from the immune and clinical models were dichotomized into high-risk and low-risk 
groups and their association with disease relapse was examined in both datasets and displayed in Kaplan-Meier (KM) curves with confidence bands (c). Differences 
between survival curves in the KM plots were determined using log-rank test. Meaningful p-values are shown for the GSE41258 validation dataset.
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In a subset of patients (n = 231) with stage, I–IV disease in 
the MECC validation dataset, both gene expression-derived 
immune infiltration estimates for 22 immune cell types and 
T cell fraction from immunoSEQ were available. Of the 22 
expression-derived immune cell infiltration scores, only CD8 
+ T cell immune infiltration considered alone performed 
slightly better (model AIC: 765.6) than T cell fraction (model 
AIC: 766.2) in predicting CRC-specific survival in multivari-
able models adjusting for known prognostic clinical variables. 
While both expression-based immune infiltration scores and 
immunoSEQ T cell fraction are independent predictors of CRC 
disease relapse, T cell fraction has a larger effect size when 
predicting disease relapse (Supplementary Table S4–S5).
Compared to other deconvolution methods, such as MCP 
counter, our method (BASE) for estimating immune infiltra-
tion using transcriptomic profiles was able to replicate known 
associations between lymphocyte infiltration (T cells) and dis-
ease relapse (Supplementary Figure S7). Using the meta- 
analysis approach for the BASE-derived immune infiltration 
estimates, we demonstrated the association of at least 9 
immune cell types with disease relapse. Applying the same 
meta-analysis framework to the MCP Counter-derived 
immune infiltration estimates, revealed that only endothelial 
cells were predictive of disease relapse risk (HR: 1.77; 95% 
CI:1.20–2.62; FDR:0.04).
CMS3 tumors are enriched in T cell subtypes and depleted 
in monocytic and macrophage infiltrates compared to 
CMS4
Given that CMS4 is defined by stromal infiltration with fibroblasts 
and macrophages and CMS1 tumors are characterized by broad 
lymphocytic infiltration, we examined the distribution of the 22 
immune cell infiltration scores across CMS groups to determine if 
each CMS group exhibits a unique immune profile (Figure 3, 
Supplementary Fig. S8). Consistently across all datasets, higher 
T cell infiltration and lower monocyte and macrophage activity 
were observed in CMS3 tumors compared to CMS4 tumors, while 
CMS1 and CMS_NA tumors were characterized by broad 
immune infiltration by all 22 immune cell types compared to 
CMS4 tumors. Notably, CMS1 tumors also exhibited higher NK 
cell infiltration than other CMS groups across all datasets (Figure 
3). The immune profile of CMS3 and CMS1 tumors may also 
explain their association with lower disease relapse risk. Using 
logistic regression, the association of CMS group with having 
a disease relapse event was assessed collectively across all three 
datasets revealing CMS1 (OR: −0.72; p-value = 0.01) and CMS3 
(OR = −0.62; p-value = 0.02) tumors are associated with a lower 
odds of having a disease relapse event.
The VEGF ligand-receptor pathway correlates positively 
with memory T cell infiltration and negatively with 
monocytic infiltration
Finally, we aimed to discover potential interactions between 
immune cell types and tumor cells in the microenvironment 
that influence disease relapse. We first determined the associa-
tion between pathway (gene sets) activity and disease relapse 
using multivariable Cox regression adjusting for clinical vari-
ables. Next, we examined the correlation between pathways 
and immune infiltration estimates for pathways and immune 
cell types which were independently found to associate with 
disease relapse (Table 3, Table S6–S11, Supplementary Fig. S9– 
S10). This approach allowed us to identify three key pathways 
Table 2. The performance of nine models for predicting CRC relapse was com-
pared in two datasets – MCC and GSE41258. All multivariable Cox proportional 
hazards regression models for a given dataset were compared to one another 
using the Akaike Information Criterion (AIC) and the likelihood ratio test (LRT).
Model Predictors
cHR (95% 
CI) SE p-value AIC
LRT 
p-value




0.05 0.02 238.1 0.02




0.04 0.03 239.1 0.03
MCC: H3 CD8+ T Cell 0.92 (0.84, 
0.99)
0.04 0.04 239.5 0.03
MCC: H4 CD4+ Naïve T Cell 0.91 (0.83, 
0.99)
0.05 0.04 239.3 0.03
MCC: H5 Neutrophil 1.06 (1.0, 
1.1)
0.03 0.04 239.8 0.04
MCC: H6 Monocyte 1.07 (1.01, 
1.15)
0.03 0.03 238.9 0.02
MCC: H7 CMS1 0.39 (0.10, 
1.53)
0.68 0.17
CMS2 0.30 (0.10, 
0.89)
0.55 0.03
CMS3 0.29 (0.09, 
0.97)
0.60 0.04




MCC: H8 CD8A 0.99 (0.76, 
1.30)
0.14 0.97 243.9 0.97
MCC: H9 CD3D 0.84 (0.60, 
1.19)
0.18 0.33 243.0 0.34




0.07 0.04 178.2 0.03




0.07 0.007 175.1 0.006
GSE41258:H3 CD8+ T Cell 0.80 (0.71, 
0.93)
0.07 0.001 172.4 0.001
GSE41258:H4 CD4+ Naïve T Cell 0.93 (0.84, 
1.04)
0.05 0.2 180.9 0.2
GSE41258:H5 Neutrophil 1.1 (0.99, 
1.24)
0.06 0.06 179.1 0.06
GSE41258:H6 Monocyte 1.11 
(1.00,1.25) 0.06 0.04 178.4 0.04
GSE41258: 
H7
CMS1 0.53 (0.09, 
3.30)
0.92 0.49
CMS2 0.31 (0.08, 
1.21)
0.68 0.09
CMS3 0.32 (0.03, 
2.93)
1.12 0.31






CD8A 0.81 (0.39, 
1.66)




(0.27,1.47) 0.43 0.29 181.4 0.27
Note: . H1   H6 : R ¼ β̂1aþ β̂2sþ β̂3t þ β̂4m þ β̂5ImmuneCell. 
H7 : R ¼ β̂1aþ β̂2sþ β̂3t þ β̂4m þ β̂5CMS1þ β̂6CMS2þ β̂7CMS3þ β̂8CMS4. 
H8 : R ¼ β̂1aþ β̂2sþ β̂3t þ β̂4m þ β̂5CD8A. H9 : R ¼ β̂1aþ β̂2sþ β̂3t þ
β̂4m þ β̂5CD3D; where a is age at diagnosis, s is sex, m is pathological stage 
at diagnosis, ImmuneCell is tumor infiltration by either CD4+ Memory Resting 
T Cells, CD4+ Memory Activated T Cells, CD8+ T Cells, CD4+ Naïve T Cells, 
Neutrophils, or Monocytes. CD8A is the gene expression of CD8A, and CD3D is 
the gene expression of CD3D. For the CMS H3 models, CMS4 is the reference 
group. For the MCC dataset, t is adjuvant therapy recipient status, while for the 
GSE41258 dataset, t is microsatellite instability status (MSI), where MSI-low 
tumors were categorized as microsatellite stable (MSS).
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in both the MCC and GSE41258 datasets that negatively cor-
related with CD4+ memory resting T cell and CD8+ T cell 
infiltration and positively correlated with monocyte infiltration 
(Supplementary Fig. S10). These pathways were: SIGNALING_ 
BY_HIPPO, VEGF_LIGAND_RECEPTOR_INTERACTIO 
NS, and RECEPTOR_LIGAND_BINDING_INITIATES_ 
THE_SECOND_PROTEOLYTIC_CLEAVAGE_OF_NOTC-
H_RECEPTOR (Supplementary Fig. S9–S10). Overall, these 
results suggest tumor pathway activity and tumor immune 
infiltration jointly influence disease relapse risk, and potential 
tumor-immune interactions that together may influence 
relapse can be determined from transcriptomic data.
Discussion
In summary, we demonstrated that gene expression-derived 
estimates of adaptive and innate immune cell type in the TME 
have strong prognostic value beyond current expression-based 
Figure 3. Consensus Molecular Subtype (CMS) association with immune infiltration and disease relapse. Relative immune infiltration across CMS groups was determined 
by examining the median difference between the immune infiltration in each CMS and the reference CMS4 (left). High immune infiltration is shown in red and low 
immune infiltration is shown in blue. Distribution of CMS tumors in patients who either did or did not exhibit disease relapse (a and b) or who either did nor did not die 
from CRC (c) was examined in four independent datasets for stage I–III tumors and is displayed in tables (right). Using a logistic regression framework, we assessed the 
collective effect of CMS distribution on disease relapse in stage I–III tumors across all four datasets, while adjusting for age, sex, stage, and dataset attributes.
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biomarkers. By combining transcriptomic data with bioinfor-
matic deconvolution methods, we inferred tumor immune 
infiltration by 22 immune cell types and showed that transcrip-
tome-based inferences about the TME are predictive of disease 
relapse. Specifically, in a joint meta-analysis of four cohorts, 
CD4+ memory activated T cell tumor infiltration was the 
strongest predictor of disease relapse even after accounting 
for known prognostic indicators including adjuvant therapy. 
Other immune cell types significantly associated with disease 
relapse based on the results from our meta-analysis include NK 
resting and activated cells, monocytes, resting mast cells, neu-
trophils, M1 and M2 macrophages, activated dendritic cells, 
and CD8+ T cells. Our results on the association of M2 macro-
phage and neutrophil infiltration with poor disease prognosis 
align well with previous studies and demonstrate the utility of 
examining both adaptive and immune cell infiltration.24 We 
also demonstrated that transcriptome-derived immune infil-
tration estimates of CD4+ memory T cells, CD8+ T cells, and 
monocytes are better predictors of disease relapse than CMS 
group classification, CD8A expression, and CD3D expression. 
Our results also suggest that both expression-based immune 
cell estimates and immunoSEQ-derived relative T cell fraction 
estimates are independent predictors of disease relapse. 
However, it appears that each method detects different under-
lying biology (Supplementary Table S5) given the strong inde-
pendent performance of each predictor in joint modeling 
analyses. In comparison to other deconvolution approaches, 
such as MCP counter, our transcriptome-derived immune 
infiltration method (BASE) was able to replicate known asso-
ciations of lymphocytic and myeloid-lineage cell infiltration 
with disease relapse. We also highlighted the importance of 
examining both adaptive and innate immune cell subtypes in 
the TME. Monocytic subpopulations in the TME are known 
potent immune suppressors that can facilitate tumor dissemi-
nation by inducing EMT/cancer stem cell phenotypes and 
promote M2 macrophage polarization.25 Memory T cells tar-
geting oncogenic mutations can be detected in peripheral 
blood of patients with metastatic CRC making these antigen- 
experienced CD4+ memory T cells highly suitable for adoptive 
T cell therapy.26 Therefore, selecting candidates with high CD4 
+ memory T cell infiltration for adoptive T cell therapy would 
be highly favorable.
Overall, our study underscores the use of transcriptome- 
derived tumor immune infiltration estimates as a biomarker 
for predicting disease relapse in CRC patients with stage I–III 
disease. This is particularly valuable given the lack of biomar-
kers, with the exception of CEA at the time of diagnosis, for 
predicting disease relapse in high-risk patients.
CMS3 tumors demonstrate T cell enrichment and 
macrophage and monocyte depletion compared to CMS4 
tumors
We showed that high T cell infiltration, particularly by the CD8 
+ and CD4+ memory T cell subsets and low macrophage and 
monocyte infiltration was consistently observed in the CMS1 
and CMS3 groups compared to CMS4 tumors (Figure 2, 
Supplementary Fig. S9). Our findings on high lymphocytic 
and NK cell activity in CMS1 tumors compared to CMS4 
tumors align well with previous studies that have demonstrated 
high lymphocytic infiltration in CMS1 tumors and high mono-
cyte and myeloid cell infiltration in CMS4 tumors.27 Moreover, 
our logistic regression results suggest CMS1 and CMS3 tumors 
are associated with not having a disease relapse event. These 
findings align with our previous work demonstrating that the 
CMS3 phenotype is selectively excluded in CRC metastases 
compared to primary tumors, such that CMS3 tumors were 
never observed in lung and liver CRC metastases.16 Our obser-
vation of high T cell activity and low monocyte activity in 
CMS3 tumors is supported by previous observations28 and 
may explain their potential exclusion from metastases as well 
as why patients with CMS3 primary tumors in the GSE41258, 
MCC, and GSE39582 datasets exhibited fewer disease relapse 
events. This has potential implications for assessing disease 
prognosis based on the CMS phenotypes. Last, while the 
Table 3. CD4+ Memory Resting T Cell infiltration and tumor pathway enrichment correlation in the MCC cohort. Spearman rank correlation was used to determine the 
association between tumor pathway activity and CD4+ Memory Resting T Cell infiltration scores. Tumor pathways from the C2. Reactome collection in MSigDB were 
selected if they associated with disease relapse in a multivariable regression model (FDR < 0.1). The gene set size for each pathway of interest is noted. The overlap 
between gene sets defining a given tumor pathway and genes in the LM22 signature gene set is also shown. In addition, the specific overlap with CD4+ Memory Resting 
T cell defining genes is also noted.




Overlap with Immune 
Signature Genes: N (%)
Overlap with CD4+ 
Memory Resting T Cell: 
N (%)
HALLMARK_ANGIOGENESIS −0.57 P < 1*10−16 36 3 (8.33%) 0 (0%)
REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION −0.55 P < 1*10−16 87 8 (9.20%) 0 (0%)
REACTOME_L1CAM_INTERACTIONS −0.53 3.84*10−11 86 0 (0%) 0 (0%)
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION −0.52 9.97*10−11 200 1 (0.5%) 0 (0%)
REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM −0.52 1.64*10−10 49 3 (6.12%) 0 (0%)
REACTOME_COLLAGEN_FORMATION −0.52 1.93*10−10 58 2 (3.45%) 0 (0%)
REACTOME_GLYCOSAMINOGLYCAN_METABOLISM −0.52 2.23*10−10 111 5 (4.50%) 0 (0%)
REACTOME_CHONDROITIN_SULFATE_BIOSYNTHESIS −0.51 5.39*10−10 21 2 (9.52%) 0 (0%)
REACTOME_VEGF_LIGAND_RECEPTOR_INTERACTIONS −0.49 4.42*10−09 10 0 (0%) 0 (0%)
REACTOME_GAP_JUNCTION_DEGRADATION −0.48 4.96*10−09 10 0 (0%) 0 (0%)
REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS −0.47 1.52*10−08 27 1 (3.70%) 0 (0%)
HALLMARK_COAGULATION −0.46 3.51*10−08 138 4 (2.90%) 1 (0.007%)
HALLMARK_HYPOXIA −0.45 5.12*10−08 200 3 (1.5%) 1 (0.005%)
Notes: Overlap with the immune signature matrix (gene set size = 547 genes) was determined by examining the number of genes shared between the immune 
signature gene set divided by the total number of genes in the pathway of interest. Overlap with genes n(= 66) defining the CD4+ Memory Resting T cell signature 
was determined in a similar manner.
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focus of this study is the relationship between disease relapse 
and immune infiltration, we did examine the association of 22 
specific immune cell types with disease-specific survival in 
patients with stage IV disease from all four datasets as well as 
in patients from the two GSE datasets with stage IV micro-
satellite stable (MSS) disease (Supplementary Fig. S11) using 
our meta-analysis framework. As these cohorts were relatively 
small and most likely underpowered, no specific immune cell 
type was found to be significantly associated with CRC-specific 
survival. However, interestingly, we did note that unlike in the 
disease relapse analyses, NK activated cells may be associated 
with shorter CRC-specific survival in patients with stage IV 
disease and in patients with stage IV MSS disease.
Potential interactions between VEGF-tumor pathway 
activity and T cells may have therapeutic value
Understanding tumor immune interactions is essential as was 
demonstrated by studies examining the joint utility of tumor- 
inflamed gene expression profile (GEP) and tumor mutation 
burden in predicting PD-1 checkpoint blockade response 
across multiple tumor types.29 Therefore, we aimed to discover 
potential tumor immune interactions by examining if specific 
immune cell subtypes that are known to associate with disease 
relapse are also associated with specific oncogenic pathways. As 
such, we examined correlations between tumor immune infil-
tration estimates and tumor pathway activity. We found 3 
main pathways which were independently associated with dis-
ease relapse and correlated with T cell and monocyte infiltra-
tion of which the VEGF_LIGAND_RECEPTOR_INTERAC 
TIONS pathway was the most clinically relevant. VEGF ligand 
receptors are required for the recruitment and migration of 
monocytes, macrophages, and hematopoietic precursors. 
Moreover, tumor angiogenesis is directly regulated by VEGF- 
A and VEGFR2, and VEGF inhibitor therapy with Bevacizum 
ab is a first-line regimen for metastatic CRC, albeit the gain in 
survival made with Bevacizumab has been modest.30 Given the 
association of the VEGF ligand-receptor pathway with mono-
cyte and T cell infiltration, our studies suggest that combining 
anti-angiogenic drug targets with immunotherapy agents may 
be promising, and that VEGF inhibitor therapies may yield 
better results if used in a subset of patients with high monocyte 
and low T cell infiltration prior to metastatic progression.
Study limitations and future directions
We examined the relationship between molecular and clinical 
variables, most notably, adjuvant therapy receipt, CMS groups, 
and MSI, and gene-expression derived tumor immune infiltra-
tion to comprehensively determine the independent associa-
tion of gene-expression derived immune infiltration on disease 
relapse. This is particularly valuable in the setting of immu-
notherapy, such as adoptive T cell transfer therapy, where 
selecting patients with high CD4+ memory T cell populations 
would be advantageous.26 Although gene expression panels 
examining molecular profiles such as CMS and tumor immune 
profiles are not part of the standard repertoire of molecular 
assays available in a clinical setting, such profiling of tumors is 
becoming increasingly common in clinical research settings31 
and have utility for stratifying patients into high and low-risk 
groups in the setting of clinical trials. However, this study 
should be considered in the context of its limitations. Althou 
gh adjuvant therapy information was abstracted, information 
on the type and duration of treatment was incomplete. 
Moreover, the accuracy of distinguishing between resting and 
activated cell states is limited. Therefore, establishing immune 
signatures for distinct cell states at the bulk tumor level would 
immensely benefit from future work at the single-cell level, 
where individual cell states can be better delineated.
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